On April 26, 2023 RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, reported that it will present a poster on FLX475, its lead oncology drug candidate, at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL (Press release, RAPT Therapeutics, APR 26, 2023, https://investors.rapt.com/news-releases/news-release-details/rapt-therapeutics-announces-flx475-poster-presentation-2023 [SID1234630542]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details:
Title: Clinical and Biological Activity of FLX475, an Oral CCR4 Antagonist, in Advanced Cancer
Session Title: Developmental Therapeutics—Immunotherapy
Session Date and Time: Saturday, June 3, 2023; 8:00 a.m. – 11:00 a.m. ET
Abstract Number: 2625
The abstract will be released on Thursday, May 25, 2023 at 5:00 p.m. ET on meetings.asco.org.